Almost a year after netting its first collaboration with Novo Nordisk A/S, TransTech Pharma Inc. has chalked up its second - this one a multiyear deal with Cephalon Inc. to discover and develop small molecules for as many as three therapeutic targets. (BioWorld Today) Read More
